Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomised trial

References

• Attebury C. E., Maddrey W. C., Conn H. O. Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy. A controlled, double-blind clinical trial. Am. Dig. Dis. 1978; 2: 398, 4061. Attebury C. E., Maddrey W. C., Conn H. O. Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy. A controlled, double-blind clinical trial. Am. Dig. Dis. 1978; 2: 398, 406
   Google Scholar
• Bac D. J., Swart G. R., van den Berg J. W. O., Wilson J. H. P. Small bowel wall function in patients with advanced liver cirrhosis and portal hypertension: studies on permeability and luminal bacterial overgrowth. Eur. J. Gastroenterol. 1993; 5: 383, 3872. Bac D. J., Swart G. R., van den Berg J. W. O., Wilson J. H. P. Small bowel wall function in patients with advanced liver cirrhosis and portal hypertension: studies on permeability and luminal bacterial overgrowth. Eur. J. Gastroenterol. 1993; 5: 383, 387
   Web of Science ®Google Scholar
• Berk D. P., Chalmers T. Deafness complicating antibiotic therapy of hepatic encephalopathy. Ann. Intern. Med. 1970; 73: 393, 3963. Berk D. P., Chalmers T. Deafness complicating antibiotic therapy of hepatic encephalopathy. Ann. Intern. Med. 1970; 73: 393, 396
   PubMed Web of Science ®Google Scholar
• Capoccia L., Ferenci P., Fisher J. E., Opolon P. Mechanisms of hepatic encephalopathy. Gastroenterol. Int. 1989; 2: 131, 1404. Capoccia L., Ferenci P., Fisher J. E., Opolon P. Mechanisms of hepatic encephalopathy. Gastroenterol. Int. 1989; 2: 131, 140
   Google Scholar
• Conn H. O. The hepatic encephalopathies. Hepatic Encephalopaty: Management with Lactulose and Related Carbohydrates, H. O. Conn, J. Bircher. Medi-Ed Press, East Lancing, Michigan 1988; 15–305. Conn H. O. The hepatic encephalopathies. Hepatic Encephalopaty: Management with Lactulose and Related Carbohydrates, H. O. Conn, J. Bircher. Medi-Ed Press, East LancingMichigan 1988; 15–30
   Google Scholar
• Conn H. O. The theoretic therapy of hepatic encephalopathy. Hepatic Encephalopaty: Management with Lactulose and Related Carbohydrates, H. O. Conn, J. Bircher. Medi-Ed Press, East Lancing, Michigan 1988; 83–946. Conn H. O. The theoretic therapy of hepatic encephalopathy. Hepatic Encephalopaty: Management with Lactulose and Related Carbohydrates, H. O. Conn, J. Bircher. Medi-Ed Press, East LancingMichigan 1988; 83–94
   Google Scholar
• Conn H. O., Leevy C. M., Vlahcevic Z. R., Rodgers J. B., Maddrey W. C., Seeff L. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. Gastroenterology 1977; 72: 573, 5837. Conn H. O., Leevy C. M., Vlahcevic Z. R., Rodgers J. B., Maddrey W. C., Seeff L. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. Gastroenterology 1977; 72: 573, 583
   PubMed Web of Science ®Google Scholar
• Coxon A., Pallis C. A. Metronidazole neuropathy. J. Neurosurg. Psychiatry 1976; 39: 403, 4058. Coxon A., Pallis C. A. Metronidazole neuropathy. J. Neurosurg. Psychiatry 1976; 39: 403, 405
   PubMed Web of Science ®Google Scholar
• Dawson A. M., McLaren J., Sherlock S. Neomycin in the treatment of hepatic coma. Lancet 1957; 2: 1263, 12689. Dawson A. M., McLaren J., Sherlock S. Neomycin in the treatment of hepatic coma. Lancet 1957; 2: 1263, 1268
   Web of Science ®Google Scholar
• Descombe J. J., Dubourg D., Picard M., Palazzini E. Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. J. Clin. Pharmacol. Res. 1994; XIV(2)51–5610. Descombe J. J., Dubourg D., Picard M., Palazzini E. Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. J. Clin. Pharmacol. Res. 1994; XIV(2)51–56
   Google Scholar
• Di Piazza S., Filippazzo M. G., Morello S. Rifaximin vs neomycin in the treatment of porto-systemic encephalopathy. Ital. J. Gastroenterol. 1989; 23: 403, 40711. Di Piazza S., Filippazzo M. G., Morello S. Rifaximin vs neomycin in the treatment of porto-systemic encephalopathy. Ital. J. Gastroenterol. 1989; 23: 403, 407
   Google Scholar
• Eftimiadi C., De Leo C., Schito G. C. Treatment of hepatic encephalopathy with L/105, a new non-absorbable rifamycin. Eptl Clin. Res. 1984; 10: 691, 69612. Eftimiadi C., De Leo C., Schito G. C. Treatment of hepatic encephalopathy with L/105, a new non-absorbable rifamycin. Eptl Clin. Res. 1984; 10: 691, 696
   Web of Science ®Google Scholar
• Kurtz D., Zenglein J. P., Ilmer M. Etude du sommeil nocturne on cours de I'encephalopathie porto-cave. Electroencefh. Clin. Neurophysiol. 1972; 33: 167, 17813. Kurtz D., Zenglein J. P., Ilmer M. Etude du sommeil nocturne on cours de I'encephalopathie porto-cave. Electroencefh. Clin. Neurophysiol. 1972; 33: 167, 178
   PubMedGoogle Scholar
• Lefebvre I., Hesseltine H. C. The perpheral white blood cells and metronidazole. J.A.M.A. 1965; 94: 15, 1814. Lefebvre I., Hesseltine H. C. The perpheral white blood cells and metronidazole. J.A.M.A. 1965; 94: 15, 18
   Google Scholar
• Morgan M. H., Read A. E., Speller D. C. E. Treatment of hepatic encephalopathy with metronidazole. Gut 1982; 23: 1, 715. Morgan M. H., Read A. E., Speller D. C. E. Treatment of hepatic encephalopathy with metronidazole. Gut 1982; 23: 1, 7
   PubMed Web of Science ®Google Scholar
• Orlandi F., Feddara U., Candelaresi M. T., Morettini A., Corazza G. R., Di Simone A., Dobrilla G., Cavallini G. Comparison between neomycin and lactulose in 173 patients with hepatic encephalopathy. A randomized clinical trial. Dig. Dis. Sci. 1981; 26: 498, 50616. Orlandi F., Feddara U., Candelaresi M. T., Morettini A., Corazza G. R., Di Simone A., Dobrilla G., Cavallini G. Comparison between neomycin and lactulose in 173 patients with hepatic encephalopathy. A randomized clinical trial. Dig. Dis. Sci. 1981; 26: 498, 506
   PubMed Web of Science ®Google Scholar
• Parini P., Cipolla A., Salzetta A. Effect of Rifaximin in the treatment of portal-systemic encephalopathy. Cur. Therap. Res. 1992; 51: 1, 617. Parini P., Cipolla A., Salzetta A. Effect of Rifaximin in the treatment of portal-systemic encephalopathy. Cur. Therap. Res. 1992; 51: 1, 6
   Google Scholar
• Pedretti G., Calzetti C., Missale C., Fiaccadori F. Rifaximin versus neomycin on iperammoniemia in chronic porto-systemic encephalopathy on cirrhotics. A double-blind randomized trial. Ital. J. Gastroenterol. 1991; 23: 175, 17818. Pedretti G., Calzetti C., Missale C., Fiaccadori F. Rifaximin versus neomycin on iperammoniemia in chronic porto-systemic encephalopathy on cirrhotics. A double-blind randomized trial. Ital. J. Gastroenterol. 1991; 23: 175, 178
   PubMedGoogle Scholar
• Record C. O. Neurochemistry of hepatic encephalopathy. Gut 1991; 32: 1261, 126319. Record C. O. Neurochemistry of hepatic encephalopathy. Gut 1991; 32: 1261, 1263
   PubMed Web of Science ®Google Scholar
• Schenker S., Brady C. E., III. Pathogenesis hepatic encephalopathy. Hepatic Encephalopaty: Management with Lactulose and Related Carbohydrates, H. O. Conn, J. Bircher. Medi-Ed Press, East Lancing, Michigan 1988; 15–3020. Schenker S., Brady C. E., III. Pathogenesis hepatic encephalopathy. Hepatic Encephalopaty: Management with Lactulose and Related Carbohydrates, H. O. Conn, J. Bircher. Medi-Ed Press, East LancingMichigan 1988; 15–30
   Google Scholar
• Soeters P. B., Van Leeuwen P. A. M., Janssen M. A., De Broer J. E. G., Groossens H. M., Van Eyck H. M. A. Metabolic generations of ammonia and aminoacids in the intestinal wall and the influence of neomycin and lactulose. Advances in Hepatic Encephalopathy and Urea Cycle Diseases, G. Kleinberger, P. Ferenci, P. Riederer, H. Thaler. Karger, Basel 1983; 147–15321. Soeters P. B., Van Leeuwen P. A. M., Janssen M. A., De Broer J. E. G., Groossens H. M., Van Eyck H. M. A. Metabolic generations of ammonia and aminoacids in the intestinal wall and the influence of neomycin and lactulose. Advances in Hepatic Encephalopathy and Urea Cycle Diseases, G. Kleinberger, P. Ferenci, P. Riederer, H. Thaler. Karger, Basel 1983; 147–153
   Google Scholar
• Testa R., Eftimiadi C., Sukklar G. S. A non-absorbable rifamycin for treatment of hepatic encephalopathy. Drugs Exptl Clin. Res. 1985; 11: 387, 39222. Testa R., Eftimiadi C., Sukklar G. S. A non-absorbable rifamycin for treatment of hepatic encephalopathy. Drugs Exptl Clin. Res. 1985; 11: 387, 392
   PubMedGoogle Scholar
• Tisdale W. A., Fenster L. F., Klatskin G. Acute staphylococcal enterocolitis complicating oral neomycin therapy in cirrhosis. N. Engl. J. Med. 1960; 263: 1014, 101623. Tisdale W. A., Fenster L. F., Klatskin G. Acute staphylococcal enterocolitis complicating oral neomycin therapy in cirrhosis. N. Engl. J. Med. 1960; 263: 1014, 1016
   PubMed Web of Science ®Google Scholar
• Uribe M., Berthier J. M., Lewis H., Mata J. M., Sierra J. G., Garcia-Ramos G., Acosta J. R., Dehesa M., Galvan E. Lactose enemas plus placebo tablets vs neomycin tablets plus starch enemas in acute portal systemic encephalopathy. A double blind randomized controlled study. Gastroeterology 1981; 81(1)101–10624. Uribe M., Berthier J. M., Lewis H., Mata J. M., Sierra J. G., Garcia-Ramos G., Acosta J. R., Dehesa M., Galvan E. Lactose enemas plus placebo tablets vs neomycin tablets plus starch enemas in acute portal systemic encephalopathy. A double blind randomized controlled study. Gastroeterology 1981; 81(1)101–106
   PubMed Web of Science ®Google Scholar
• Venturini A. P. Pharmacokinetics of L105, a new rifamycin in rats and dogs after oral administration. Chemiotherapy 1983; 29: 1, 725. Venturini A. P. Pharmacokinetics of L105, a new rifamycin in rats and dogs after oral administration. Chemiotherapy 1983; 29: 1, 7
   PubMed Web of Science ®Google Scholar
• Venturini A. P., Marchi E., Blandino G., Mattina R. In vitro and in vivo evaluation of L 105, a new rifamycin. Chemioterapia 1982; 1(4)214A26. Venturini A. P., Marchi E., Blandino G., Mattina R. In vitro and in vivo evaluation of L 105, a new rifamycin. Chemioterapia 1982; 1(4)214A
   Google Scholar
• Von Lentzen H., Kölle E. U., Daschner F. Vergleichende untersuchung der serumspiegel und urinausscheidung nach oraler gabe von Paromomycin und Neomycin. Arzneim.-Forsch./Drug Res. 1981; 31(II)11, 1967–197127. Von Lentzen H., Kölle E. U., Daschner F. Vergleichende untersuchung der serumspiegel und urinausscheidung nach oraler gabe von Paromomycin und Neomycin. Arzneim.-Forsch./Drug Res. 1981; 31(II)11, 1967–1971
   Google Scholar
• Zieve L. The mechanism of hepatic coma. Hepatology 1981; 1: 360, 36528. Zieve L. The mechanism of hepatic coma. Hepatology 1981; 1: 360, 365
   PubMed Web of Science ®Google Scholar
• Voogd C. E. On the mutagenicity of nitroimidazoles. Mutat. Res. 1981; 86: 243, 27729. Voogd C. E. On the mutagenicity of nitroimidazoles. Mutat. Res. 1981; 86: 243, 277
   PubMed Web of Science ®Google Scholar